Herbal products and the liver: A review of adverse effects and mechanisms

Gastroenterology

Volumn 148, Issue 3, 2015, Pages 517-532.e3

  Seeff, Leonard B ^a   Bonkovsky, Herbert L ^b   Navarro, Victor J ^c   Wang, Guqi ^b  

^a Einstein Healthcare Network ^*  (United States)

^b LEVINE CANCER INSTITUTE   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

Contamination and Adulteration; Dietary Supplement Health and Education Act; Herbal Therapie; sSilymarin

Indexed keywords

ANTIVIRUS AGENT; CATECHIN; COMFREY EXTRACT; GLYCYRRHIZIC ACID; HERBACEOUS AGENT; KAVA EXTRACT; XIAO CHAI HU TANG; PLANT MEDICINAL PRODUCT;

ACTAEA RACEMOSA; ASIA; BODY BUILDING; CANADA; CHINESE MEDICINE; CLINICAL TRIAL (TOPIC); COMFREY; DIET SUPPLEMENTATION; DRUG APPROVAL; DRUG CONTAMINATION; DRUG EFFECT; DRUG MARKETING; DRUG SAFETY; EUROPEAN UNION; GERMANDER; HEPATITIS; HERBAL MEDICINE; HUMAN; LARREA; LIVER DISEASE; LIVER INJURY; LIVER TOXICITY; PRIORITY JOURNAL; REVIEW; SABAL; SILYBUM MARIANUM; STANDARDIZATION; UNITED KINGDOM; UNITED STATES; WEIGHT REDUCTION; DRUG EFFECTS; DRUG-INDUCED LIVER INJURY; LIVER; LIVER DISEASES;

DRUG-INDUCED LIVER INJURY; HUMANS; LIVER; LIVER DISEASES; PLANT PREPARATIONS;

EID: 84923902213     PISSN: 00165085     EISSN: 15280012     Source Type: Journal    
DOI: 10.1053/j.gastro.2014.12.004     Document Type: Review

References (153)

1. A.W. Jones Early discovery and rise of pharmaceutical chemistry Drug Test Anal 3 2011 337 344
2. S.-Y. Pan, G. Litscher, and S.-H. Gao Historical perspectives of traditional indigenous medical practices: the current renaissance and conservation of herbal resources Evid Based Complement Alternat Med 2014 2014 525350
3. X. Mou, S. Kesari, and P.Y. Wen Crude drugs as anticancer agents Int J Clin Med 4 2011 17 25
4. D.M. Eisenberg, R.C. Kessler, and C. Foster Unconventional medicine in the United States: prevalence, costs, and patterns of use N Engl J Med 328 1993 246 252
5. R.C. Kessler, B. Davis, and D.F. Foster Long-term trends in the use of complementary and alternative medical therapies in the United States Ann Intern Med 135 2001 262 268
6. D.M. Eisenberg, R.B. Davis, and S.L. Ettner Trends in alternative medicine use in the United State, 1990-1997: results of a follow-up national study JAMA 280 1998 1569 1575
7. G. Block, D. Cox, and J. Madans Vitamin supplement use, by demographic characteristics Am J Epidemiol 127 1988 297 309
8. J.P. Koplan, J.L. Annest, and P.M. Layde Nutrient intake and supplementation in the United States (NHANES II) Am J Public Health 76 1986 287 289
9. R.B. Ervin, J.D. Wright, and J. Kennedy-Stephenson Use of dietary supplements in the United States, 1988-1994 Vital Health Stat 11 1999 i iii 1-4
10. K. Radimer, B. Bindewald, and J. Hughes Dietary supplement use by US adults: data from the National Health and Nutrition Examination Survey, 1999-2000 Am J Epidemiol 160 2004 339 349
11. H. Ni, C. Simile, and A.M. Hardy Utilization of complementary and alternative medicine by United States adults: results from the 1999 national health interview survey Med Care 40 2002 333 358
12. J. Kennedy Herb and supplement use in the US adult population Clin Ther 27 2005 1847 1858
13. B.B. Timbo, M.O.P.P. Ross, and P.V. McCarthy Dietary supplements in a national survey: prevalence of use and reports of adverse events J Am Diet Assoc 106 2006 1966 1974
14. A. Garcia-Alvarez, B. Egan, and S. Klein Usage of plant food supplements across six European countries: findings from the PlantLIBRA Consumer Survey PLoS One 9 2014 e92265
15. R.L. Nahin, P.M. Barnes, and B.J. Stussman Costs of complementary and alternative medicine (CAM) and frequency of CAM visits to CAM practitioners: United States 2002. National Health Statistics Report; No. 18 2009 National Center for Health Statistics Hyattsville, MD
16. th consecutive year; turmeric sales jump 40% in natural channel HerbalGram 99 2013 60 65
17. A. Astin Why patients use alternative medicine. Results of a national study JAMA 279 1998 1548 1553
18. A. Metcalfe, J. Williams, and J. McChesney Use of complementary and alternative medicine by those with a chronic disease and the general population - results of a national population based survey BMC Complement Altern Med 10 2010 58
19. A. Sparber, J.C. Wootton, and L. Bauer Use of complementary medicine by adult patients participating in HIV/AIDS clinical trial J Altern Complement Med 6 2000 415 422
20. L.B. Seeff, T.M. Curto, and G. Szabo Herbal product use by persons enrolled in the Hepatitis C Antiviral Long-Term Treatment against Cirrhosis (HALT-C) Trial Hepatology 47 2008 605 612
21. E. Ernst, and S.K. Hung Great expectations: what do patients using complementary and alternative medicine hope for? Patient 4 2011 89 101
22. Junod SW. FDA and clinical drug trials: a short history. Available at: www.fda.gov/AboutFDA/WhatWeDo/History/Overviews/ucm304485.htm. Accessed January 22, 2015.
23. US Food and Drug Administration. Dietary Supplement Health and Education Act of 1994. Available at: http://www.gpo.gov/fdsys/BILLS-103s784es/pdf/BILLS-103s784es/pdf. Accessed January 22, 2015
24. T.P. Fan, G. Deal, and H.L. Koo Future development of global regulation of Chinese herbal products J Ethnopharmacol 140 2012 568 586
25. S.J. Bent Herbal medicine in the United States: review of efficacy, safety, and regulation: Grand Rounds at University of California, San Francisco Medical Center J Gen Intern Med 23 2008 854 859
26. M.R. Harkey, G.L. Henderson, and M.E. Gershwin Variability in commercial ginseng products: an analysis of 25 preparations Am J Clin Nutr 73 2001 1101 1106
27. R.B. Saper, R.S. Phillips, and A. Sehgal Lead, mercury, and arsenic in US- and Indian-manufactured Ayurvedic medicines sold over the internet JAMA 300 2008 915 923
28. E. Ernst Heavy metals in traditional Indian remedies Eur J Clin Pharmacol 57 2002 891 896
29. M.K. Wong, P. Tan, and Y.C. Wee Heavy metals in some Chinese herbal plants Biol Trace Elem 36 1993 135 142
30. F. Stickel, S. Droz, and E. Patsenker Severe hepatotoxicity following ingestion of Herbalife contaminated with Bacillus subtilis J Hepatol 50 2009 111 117
31. G.M. Miller, and R. Stripp A study of western pharmaceuticals contained within samples of Chinese herbal/patent medicines collected from New York City's Chinatown Leg Med 9 2007 258 264
32. N. Fleshler, M. Harvey, and H. Adomat Evidence for contamination of herbal erectile dysfunction products with phosphodiesterase type5 inhibitors J Urol 174 2005 636 641
33. E. Ernst Adulteration of Chinese herbal medicines with synthetic drugs: a systematic review J Intern Med 252 2002 107 113
34. C.A. Morris, and J. Avorn Internet marketing of herbal products JAMA 290 2003 1505 1509
35. US Government Accountability Office. Herbal dietary supplements: examples of deceptive or questionable marketing practices and potentially dangerous advice. Available at: http://www.gao.gov/products/GAO-10-662T. Accessed January 22, 2015.
36. "Dan Fabricant: FDA 'somewhat aghast' at degree of cGMP non-compliance." Interview with Elaine Watson, April 26, 2012. Available at: http://www.nutraingredients-usa.com/Regulation/Dan-Fabricant-FDA-somewhat-aghast-at-degree-of-cGMP-non-compliance. Accessed January 22, 2015.
37. "FDA's Dr Fabricant: GMP violations are staying the same, and that's a concern." Interview with Stephen Daniells, November 20, 2013. Available at: http://www.nutraingredients-usa.com/Regulation/FDA-s-Dr-Fabricant-GMP-violations-are-staying-the-same-and-that-s-a-concern. Accessed January 22, 2015.
38. J.-S. Chan, Y.-C. Chan, and C.-H. Chou Hepatoprotection of silymarin against thioacetamide-induced chronic fibrosis J Sci Food Agric 92 2012 1441 1447
39. Y. Wang, L. Wang, and Z. Liu In vivo evaluation of silibin nanosuspensions targeting liver J Biomed Nanotechnol 8 2012 760 769
40. E. Hashizume, R. Nakagiri, and A. Shirae Suppression of ethanol and lipopolysaccharide-induced liver injury to extracts of Hydraneae Dulcis Folium in rats Biosci Biotechnol Biochem 67 2003 1857 1863
41. D.B. Strader, B.R. Bacon, and K.L. Lindsay Use of complementary and alternative medicine in patients with liver disease Am J Gastroenterol 97 2002 2391 2397
42. G. Cravotto, L. Boffa, and L. Genzini Phytotherapeutics: an evaluation of the potential of 1000 plants J Clin Pharmacol Ther 35 2010 11 48
43. M. Shibano, A.S. Lin, and H. Itokara Separation and characterization of active flavonolignans of Silybum marianum by liquid chromatography connected with hybrid ion-trap and time-of-flight spectrometry (LC-MS/IT-TOF) J Nat Prod 70 2007 1474 1478
44. Z. Wen, T.E. Dumas, and S.J. Schrieber Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of a milk thistle extract Drug Metab Dispos 36 2008 6572
45. S.J. Schrieber, Z. Wen, and M. Vourvahis The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic fatty liver disease and correlates with plasma caspase-3/7 activity Drug Metab Dispos 39 2011 2182 2190
46. A. Bresinsky, and H. Besl Giftpilze 1985 Verlagsgesellschaft Stuttgart 18 35
47. U. Mengs, R.T. Pohl, and T. Mitchell Legalon® SIL: the antidote of choice in persons with acute hepatotoxicity from amatoxin poisoning Curr Pharm Biotech 13 2012 1964 1970
48. P. Ferenci, B. Dragosics, and H. Dittrich Randomized controlled trial of silymarin treatment in patients with cirrhosis of the liver J Hepatol 9 1989 105 113
49. J.C. Trinchet, T. Coste, and V.G. Levy Treatment of alcoholic hepatitis with silymarin. Results of a randomized double blind trial Clin Biol 13 1989 120 124
50. A. Pares, R. Planas, and M. Torres Effects of silymarin in alcoholic patients with cirrhosis of the liver: results of a controlled, double-blind, randomized and multicenter study J Hepatol 28 1998 615 621
51. K.D. Flora, M. Hahn, and H. Rosen Milk thistle (Silybum marianum) for the therapy of liver disease Am J Gastroenterol 93 1998 139 143
52. B.P. Jacobs, C. Dennehy, and G. Ramirez Milk thistle for the treatment of liver disease: a systematic review and meta-analysis Am J Med 113 2002 506 515
53. A. Rambaldi, B.P. Jacobs, and G. Iaquinto Milk thistle for alcoholic and/or hepatitis B or C liver diseases - a systematic Cochrane hepato-biliary group review with meta-analyses of randomized clinical trials Am J Gastroenterol 100 2005 2583 2591
54. P. Ferenci, T.-M. Scherzer, and H. Kerschner Silibinin is a potent antiviral agent in patients with chronic hepatitis C not responding to pegylated interferon/ribavirin therapy Gastroenterology 135 2008 1561 1567
55. U.P. Neumann, M. Biermer, and D. Eurich Successful prevention of hepatitis C virus (HCV) liver graft reinfection by silibinin mono-therapy J Hepatol 52 2010 951 952
56. P. Ferenci, and S. Beinhardt Silibinin: an old drug in the high tech era of liver transplantation J Hepatol 58 2013 409 411
57. D. Eurich, M. Bahra, and T. Berg Treatment of hepatitis C-virus-reinfection after liver transplant with silibinin in nonresponders to pegylated interferon-based therapy Exp Clin Transplant 9 2011 1 6
58. V. Bonifaz, Y. Shan, and R.W. Lambrecht Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells Liver Int 29 2009 366 373
59. M. Mehrab-Mohseni, H. Sendi, and N. Streuerwald Legalon-SIL downregulates HCV core and NS5A in human hepatocytes expressing full-length HCV World J Gastroenterol 17 2011 1694 1700
60. S.J. Polyak, C. Morishima, and M.C. Shuhart Inhibition of T-cell inflammatory cytokines, hepatocyte NF-kappaB signaling, and HCV infection by standardized silymarin Gastroenterology 132 2007 1925 1936
61. A. Ahmed-Belkacem, N. Ahnou, and L. Barbotte Silibinin and related compounds are direct inhibitors of hepatitis C virus RNA-dependent RNA polymerase Gastroenterology 136 2010 1112 1122
62. S.J. Polyak, P. Ferenci, and J.M. Pawlotsky Hepatoprotective and antiviral functions of silymarin components in hepatitis C virus infection Hepatology 57 2013 1262 1271
63. M.W. Fried, V.J. Navarro, and N. Afdahl Effect of silymarin (milk thistle) on liver disease in patients with chronic hepatitis C unsuccessfully treated with interferon therapy: a randomized controlled trial JAMA 308 2013 274 282
64. L. Zhang, G. Wang, and W. Hou Contemporary clinical research of traditional Chinese medicines for chronic hepatitis B in China: an analytic review Hepatology 51 2010 690 698
65. S. Luper A review of plants used in the treatment of liver disease: part 1 Altern Med Rev 4 1998 178 188
66. L. Mollica, F. De Marchis, and C. Daliacosta Glycyrrhizin binds to high mobility group 1 box protein and inhibits its cytokine activities Chem Biol 14 2007 431 441
67. H. Kumada Long-term treatment of chronic hepatitis C with glycyrrhizin (stronger neominophagen C [SNMC]) for preventing liver cirrhosis and hepatocellular carcinoma Oncology 62 suppl 1 2002 94 100
68. I. Hidaka, K. Hino, and M. Korenaga Stronger Neominophagen C, a glycyrrhizin-containing preparation, protects liver against carbon tetrachloride-induced oxidative stress in transgenic mice expressing the hepatitis C virus polyprotein Liver Int 27 2007 845 853
69. T.G. Van Rossum, A.G. Vutto, and W.A. Hop Intravenous glycyrrhizin for treatment of chronic hepatitis C: a double-blind, randomized, placebo-controlled phase I/II trial J Gastroenterol Hepatol 14 1999 1093 1099
70. S.K. Acharya, G. Dasarathy, and A. Tandon A preliminary trial on interferon stimulator (SNMC) derived from Glycyrrhizin glabra in the treatment of subacute hepatic failure Indian J Med Res 98 1993 69 74
71. M.P. Manns, H. Wedemeyer, and A. Singer Glycyrrhizin in patients who failed interferon alpha-based therapies: biochemical and histological effects after 52 weeks J Viral Hepat 19 2012 537 546
72. M.J. Hsu, J.S. Cheng, and H.C. Huang Effect of saikosaponin, a triterpine saponin, on apoptosis in lymphocytes: association with cmyc, p53, and bcl-2 mRNA Br J Pharmacol 131 2000 1285 1293
73. L.C. Chiang, L.T. Ng, and D.E. Shieh Cytotoxicity and anti-hepatitis B virus activities of saikosaponins from Bupleurum species Planta Med 69 2003 705 709
74. I. Shimizu Sho-saiko-to: Japanese herbal medicine for protection against hepatic fibrosis and carcinoma J Gastroenterol Hepatol 15 suppl 2000 D84 D90
75. C. Hirayama, M. Okomura, and K. Tanikawa A multicenter randomized controlled clinical trial of Sho-saiko-to in chronic active hepatitis Gastroenterol Jpn 24 1989 713 719
76. H. Tajiri, K. Kozaiwa, and Y. Ozaki Effect of sho-saiko-to (xiao-chai-hu-tang) on HBeAg clearance in children with hepatitis B virus infection and with sustained liver disease Am J Clin Med 19 1991 121 129
77. G. Deng, R.C. Kurtz, and A. Vickers A single arm phase II study of a Far-Eastern traditional herbal formulation (sho-saiko-to or xiao-chai-hu-tang) in chronic hepatitis C patients J Ethnopharmacol 136 2011 83 87
78. H. Oka, S. Yamamoto, and T. Kuroki Prospective study of chemoprevention of hepatocellular carcinoma with Sho-saiko-to (TJ-9) Cancer 76 1995 743 749
79. J.K. Lee, J.H. Kim, and H.K. Shin Therapeutic effect of the oriental medicine Sho-saiko-to in liver cirrhosis and carcinoma Hepatol Res 41 2011 825 837
80. L.B. Seeff, F. Stickel, and V. Navarro Hepatotoxicity of herbal and dietary supplements N. Kaplowitz, L. DeLeve, Drug-induced liver disease 3rd ed. 2013 Elsevier Amsterdam 631 657
81. R.J. Fontana, P.B. Watkins, and H.L. Bonkovsky Rationale, design and conduct of the Drug Induced Liver Injury Network prospective study Drug Saf 32 2009 55 68
82. V.J. Navarro, H.X. Barnhart, and H.L. Bonkovsky Liver injury from herbals and dietary supplements in the U.S. Drug-Induced Liver Injury Network Hepatology 60 2014 1399 1408
83. P.W. Whiting, A. Clouston, and P. Kerlin Black cohosh and other herbal remedies associated with acute hepatitis Med J Aust 177 2002 440 443
84. J. Levitsky, T.A. Alli, and J. Wisecarver Fulminant liver failure associated with the use of black cohosh Dig Dis Sci 50 2005 538 539
85. C.R. Lynch, M.E. Folkers, and W.R. Hutson Fulminant hepatic failure associated with the use of black cohosh: a case report Liver Transpl 12 2006 989 992
86. G.B. Mahady, T. Low Dog, and M.L. Barrett United States Pharmacopeia review of the black cohosh case reports of hepatotoxicity Menopause 15 2008 628 638
87. B. Naser, J. Schnitker, and M.J. Minkin Suspected black cohosh hepatotoxicity: no evidence by meta-analysis of randomized controlled clinical trials for isopropanolic black cohosh extract Menopause 18 2011 366 375
88. J.D. Lambert, M.J. Kennett, and S. Sang Hepatotoxicity of high oral dose (-)-epigallocatechin-3-gallate in mice Food Chem Toxicol 48 2010 409 416
89. H.L. Bonkovsky Hepatotoxicity associated with supplements containing Chinese green tea (Camellia sinensis) Ann Intern Med 144 2006 68 71
90. G. Mazzanti, F. Mennito-Ippolito, and P.A. Moro Hepatotoxicity from green tea: a review of the literature and two unpublished cases Eur J Clin Pharmacol 65 2009 331 341
91. H. Inoue, M. Maeda-Yamamoto, and A. Nesumi Low and medium but not high doses of green tea polyphenols ameliorated dextran sodium sulfate-induced hepatotoxicity and nephrotoxicity Biosci Biotechnol Biochem 77 2013 1223 1228
92. R.J. Church, D.M. Gatti, and J.S. Eaddy Identification of genomic regions linked to epigallocatechin gallate induced liver toxicity using the diversity outbred stock (abstr 183) The Toxicologist 132 2013 38
93. N.M. Sheikh, R.M. Philen, and L.A. Love Chaparral-associated hepatotoxicity Arch Intern Med 157 1997 913 919
94. W.B. Batchelor, J. Heathcote, and I.R. Wanless Chaparral-induced hepatic injury Am J Gastroenterol 90 1995 831 833
95. M. Katz, and F. Saibil Herbal hepatitis: subacute hepatic necrosis secondary to chaparral leaf J Clin Gastroenterol 12 1990 203 206
96. B.N. Tandon, R.K. Tandon, and H.D. Tandon An epidemic of veno-occlusive disease of liver in Central India Lancet 2 1976 271 272
97. C.F.M. Weston, B.T. Cooper, and J.D. Davies Veno-occlusive disease of the liver secondary to ingestion of comfrey Br Med J 295 1987 183
98. A.E. Stillman, R.J. Huxtable, and P. Consroe Hepatic venocclusive disease due to pyrrolizidine (Senecio) poisoning in Arizona Gastroenterology 73 1977 349 352
99. G. Bras, D.B. Jeliffe, and K.L. Stuart Venoocclusive disease of the liver with non-portal type of cirrhosis occurring in Jamaica Arch Pathol 57 1954 285 300
100. D. Larrey, T. Vial, and A. Pauwels Hepatitis after Germander (Teucrium chamaedrys) administration: another instance of herbal medicine hepatotoxicity Ann Intern Med 117 1992 129 132
101. D. Fau, M. Lekehal, and G. Farrell Diphteroids from germander on herbal medicine induce apoptosis in isolated rat hepatocytes Gastroenterology 113 1997 1334 1346
102. S. Russmann, B.H. Lauterburg, and A. Helblng Kava hepatotoxicity Ann Intern Med 135 2001 68 69
103. F. Stickel, H.M. Baumuller, and K.H. Seitz Hepatitis induced by Kava-Kava (Piper methysticum rhizoma) J Hepatol 39 2003 62 67
104. Centers for Disease Control and Prevention. Hepatic toxicity possibly associated with kava-containing products - United States, Germany, and Switzerland JAMA 289 2003 36 37
105. P.A. Whitton, A. Lau, and A. Salisbury Kava lactones and the kava-kava controversy Phytochemistry 64 2003 673 679
106. S. Hamid, G. Rojter, and J. Vierling Protracted cholestatic hepatitis after the use of prostata Ann Intern Med 127 1997 169 170
107. F. Lapi, E. Gallo, and E. Giocaliere Acute liver damage due to Serenia repens: a case report Br J Clin Pharmacol 69 2010 558 560
108. Y.N. Singh, A.K. Devkota, and D.C. Sneeden Hepatotoxicity potential of saw palmetto (Serenoa repens) in rats Phytomedicine 14 2007 204 208
109. P.I. Zhao, C. Wang, and W. Liu Causes and outcomes of liver failure in China PLoS One 8 2013 e80991
110. P.I. Zhao, C. Wang, and W. Liu Acute liver failure associated with traditional Chinese medicine: report of 30 cases from seven tertiary hospitals in China Crit Care Med 42 2014 e296 e299
111. S. Itoh, A. Marutami, and T. Nishijima Liver injury induced by herbal medicine syo-saiko-to (xiao-chai-hu-tang) Dig Dis Sci 40 1995 1845 1848
112. N. Mantani, T. Kogure, and S. Sakai Incidence and clinical features of liver injury related to Kampo (Japanese herbal) medicine in 2,496 cases between 1979 and 1999: problems of the lymphocyte transformation test as a diagnostic method Phytomedicine 9 2002 280 287
113. F. Ikagami, M. Sumino, and M. Fujii Pharmacology and toxicology of Bupleurum root-containing Kampo medicine in clinical use Hum Exp Toxicol 25 2006 481 494
114. C.H.I. Lee, J.D. Wang, and P.C. Chan Risk of liver injury associated with Chinese herbal products containing radix bupleuri in 639,799 patients with hepatitis B virus infection PLoS One 6 2011 e16064
115. E. Elinav, G. Pinsker, and R. Safadi Association between consumption of Herbalife nutritional supplements and acute hepatotoxicity J Hepatol 47 2007 514 520
116. A.M. Schoepfer, A. Engel, and K. Fattinger Herbal does not mean innocuous: Ten cases of severe hepatotoxicity associated with dietary supplements from Herbalife products J Hepatol 47 2007 521 526
117. G. Manso, L. Lopez-Rivas, and M. Vega Continuous reporting of new cases in Spain supports the relationship between Herbalife products and liver injury Pharmacoepidemiol Drug Saf 20 2011 1080 1087
118. D. Halegoua-De Marzio, M. Vega, and J. Schifter-Weber An international effort to assess hepatotoxicity associated with some Herbalife® products (abstr 360) Hepatology 58 suppl 2013 383A
119. T. Stevens, A. Qadri, and N.N. Zein Two patients with acute liver injury associated with the use of the herbal weight-loss supplement Hydroxycut Ann Intern Med 142 2005 477 478
120. F.P. Jones, and A.H. Andrews Acute liver injury associate with the herbal supplement Hydroxycut in a soldier deployed in Iraq Am J Gastroenterol 102 2007 2357
121. L. Dora, J. Hewett, and K. Lim Hydroxycut hepatotoxicity. A case series and review of the liver toxicity from herbal weight loss supplements World J Gastroenterol 14 2008 6999 7004
122. T. Fong, K.C. Klontz, and A. Canas-Coto Hepatotoxicity due to Hydroxycut: a case series Am J Gastroenterol 105 2010 1561 1566
123. OxyElite Pro supplements recalled. Available at: www.fda.gov/ForConsumers/ConsumerUpdates/ucm374742.htm. Accessed January 22. 2015.
124. M.M. Roytman, P. Porzgen, and C.L. Lee Outbreak of severe hepatitis linked to weight-loss supplement OxyELITE Pro Am J Gastroenterol 109 2014 1296 1298
125. A.M. Isharkawy, S. McPherson, and S. Masson Cholestasis secondary to anabolic steroid use in young men Br Med J 344 2012 e468
126. A. Timchec-Hariri, M. Balali-Mood, and E. Aryan Toxic hepatitis in a group of 20 male body-builders taking dietary supplements Food Chem Toxicol 50 2012 3826 3832
127. V. Singh, M. Rudraraju, and E. Carey Severe hepatotoxicity caused by a Methasteron-containing performance-enhancing supplement J Clin Gastroenterol 43 2009 287
128. D.J. Martin, B.J. Partridge, and W. Shields Hepatotoxicity associated with the dietary supplement N.O.-XPLODE Ann Intern Med 159 2013 503 504
129. Y. El Sherrif, J.R. Potts, and M.R. Howard Hepatotoxicity from anabolic androgenic steroids marketed as dietary supplements: contribution from ATP8B1/ABCB11 mutations? Liver Int 33 2013 1266 1270
130. Bodybuilding products and hidden steroids: enforcement barriers. Available at: http://www.fda.gov/newsevents/testimony/ucm184497.htm. Accessed January 22, 2015.
131. A.L. Villela, C. Limsuwat, and D.R. Wlliams Cholestatic jaundice as a result of combination designer supplement ingestion Ann Pharmacother 47 2013 e33
132. C. Bunchorntavakul, and K.R. Reddy Review article: herbal and dietary supplement hepatotoxicity Aliment Pharmacol Ther 37 2013 3 17
133. R.J. Fontana, L.B. Seeff, and R.J. Andrade Standardization of nomenclature and causality assessment in drug-induced liver injury: summary of a clinical research workshop Hepatology 52 2010 730 742
134. G. Danan, and C. Benichou Causality assessment of adverse reactions to drug - I. A novel method based on the conclusions of international meetings: application to drug-induced liver injuries J Clin Epidemiol 46 1993 1323 1330
135. C. Benichou, G. Danan, and A. Flahault Causality assessment of adverse reactions to drugs - II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge J Clin Epidemiol 46 1993 1331 1336
136. G.P. Aithal, P.B. Watkins, and D.J. Andrade Case definition and phenotype standardization in drug-induced liver injury Clin Pharmacol Ther 89 2011 806 815
137. J. Rochon, P. Protiva, and L.B. Seeff Reliability of the Roussel Uclaf Causality Assessment Method for assessing causality in drug-induced liver injury Hepatology 48 2008 1175 1183
138. H. Suzuki, S. Yamamoto, and C. Hirayama Cianadilol therapy for HBe-antigen-positive chronic hepatitis: a multicentre, double-blind study Liver 6 1986 35 44
139. G. Shoba, D. Joy, and T. Joseph Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers Planta Med 64 1998 259 265
140. S. Luper A review of plants used in the treatment of liver disease: part 1 Altern Med Rev 4 1998 178 188
141. K.B. Soni, and A. Rajan Kuttan. Reversal of aflatoxin induced liver damage by turmeric and curcumin Cancer Lett 1997 115 121
142. M. Susan, and M.N. Rao Induction of glutathione S-transferase activity by curcumin in mice Arzneimittelforschung 42 1992 962 964
143. C. Ramprasad, and M. Sirsi Effect of Rauvolfia alkaloids on biliary secretion Indian Med Assoc 28 1957 307 309
144. Y. Jiao, J. Wilkinson IV, and X. Di Curcumin, a cancer chemopreventive and chemotherapeutic agent, is a biologically active iron chelator Blood 113 2009 462 469
145. G.L. Floersheim, A. Bieri, and R. Koenig Protection against Amanita phalloides by the iridoid glycoside mixture of Picrorhiza kurroa (kutkin) Agents Actions 29 1990 386 387
146. A.B. Vaidya, D.S. Antarkar, and J.C. Doshi Picrorhiza kurroa (kutaki) Royle ex Benth as a hepatoprotective agent - experimental and clinical studies J Postgrad Med 42 1996 105 108
147. J. Liu, H. Lin, and H. McIntosh Genus Phyllanthus for chronic hepatitis B virus infection: a systematic review J Viral Hepat 8 2001 358 366
148. M. Ott, S.P. Thygarajan, and S. Gupta Phyllanthus amarus suppresses hepatitis B virus by interrupting interactions between HBV enhancer 1 and cellular transcription factors Eur J Clin Invest 27 1997 908 915
149. P.S. Venkateswaran, I. Millman, and B.S. Blumberg Events of an extract from Phyllanthus niruri on hepatitis B and woodchuck hepatitis viruses: in vitro and in vivo studies Proc Natl Acad Sci U S A 84 1987 274 278
150. C.D. Lee, M. Ott, and S.P. Thygaranan Phyllanthus amarus down-regulates hepatitis B virus mRNA transcription and replication Eur J Clin Invest 26 1996 1069 1076
151. S.P. Thygarajan, S. Subramanian, and T. Thirunalasundari Effect of Phyllanthus amarus on chronic carriers of hepatitis B virus Lancet 2 1988 764 766
152. V. Thamlikitkul, S. Wasuwat, and P. Kanchanapee Efficacy of Phyllanthus amarus for eradication of hepatitis B virus in chronic carriers J Med Assoc Thai 74 1991 381 385
153. A. Leelarasamee, S. Trakulsomboon, and P. Maunwongyathi Failure of Phyllanthus amarus to eradicate hepatitis B surface antigen from symptomless carriers Lancet 335 1990 1600 1601